Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,053 INR | -0.68% | +1.82% | +23.34% |
Apr. 29 | Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines | MT |
Apr. 25 | Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 | MT |
Sales 2024 * | 121B 1.46B | Sales 2025 * | 140B 1.68B | Capitalization | 299B 3.59B |
---|---|---|---|---|---|
Net income 2024 * | 33.36B 400M | Net income 2025 * | 11.13B 133M | EV / Sales 2024 * | 2.63 x |
Net Debt 2024 * | 19.84B 238M | Net cash position 2025 * | 3.08B 36.92M | EV / Sales 2025 * | 2.11 x |
P/E ratio 2024 * |
41.8
x | P/E ratio 2025 * |
24.6
x | Employees | 15,556 |
Yield 2024 * |
0.22% | Yield 2025 * |
0.27% | Free-Float | 49.03% |
Latest transcript on Glenmark Pharmaceuticals Limited
1 day | -0.68% | ||
1 week | +1.82% | ||
Current month | +9.90% | ||
1 month | +7.21% | ||
3 months | +17.59% | ||
6 months | +40.41% | ||
Current year | +23.34% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | - | |
Chief Executive Officer | 54 | 98-10-11 | |
Ulhas Dhuppad
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 20-08-13 | |
Cherylann Pinto
BRD | Director/Board Member | 56 | 99-10-05 |
Chief Executive Officer | 54 | 98-10-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +1.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1,053 | -0.68% | 845 251 |
24-05-02 | 1,060 | +0.31% | 324,107 |
24-04-30 | 1,057 | -1.30% | 952,244 |
24-04-29 | 1,071 | -0.76% | 442,802 |
24-04-26 | 1,079 | -0.09% | 475,440 |
Delayed Quote NSE India S.E., May 03, 2024 at 06:12 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+23.34% | 3.59B | |
+19.98% | 43.67B | |
+20.67% | 22.51B | |
+14.75% | 14.6B | |
+14.32% | 13.74B | |
+44.72% | 11.91B | |
-8.37% | 7.04B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+10.21% | 5.42B |
- Stock Market
- Equities
- GLENMARK Stock